This blog is for whoever chooses to move their office during the holiday season in Austin, TX. If you are one of those brave few souls, here are my key takeaways/tips for you

Dear ClearCam Friends and Investors,

As the year comes to an end, I wanted to connect with you and re-cap what we have accomplished in 2021 and what we are looking forward to in the New Year.

The pandemic has presented many challenges for everyone. For young companies, face-to-face interactions and the ability to demo a product to customers as they hold and inspect it is simply irreplaceable.

In-person surgical conferences becoming available for exhibitors is exactly what our ClearCam team needed to launch into the next growth stage. We’ve participated in two conferences and were delighted with our experience!

ClearCam has reached a new milestone at a record pace! Just a few months after completing 100 successful clinical cases in March, we have now completed 200 cases. Read on for key takeaways from our more recent commercial pilots!

Written by Morgan Mosiman, Marketing and Communications

ClearCam launched the Kelling device for initial human use in September 2020. While the initial in-vivo lens cleaning performance was promising, we heard from surgeons one consistent area of feedback, “I wish it was a little easier to use.” Read on for our uncovering of the true customer need associated with this repeated request…

Written by Christopher Idelson, PhD, Co-Founder, CTO

ClearCam’s goal to perform 100 cases before making a public announcement to nationwide media was reached on March 24, 2021. We were able to prove the clinical relevance that the Kelling device was effective for clearing a laparoscope of fat, condensation, blood, and other surgical debris, without removing it from the patient’s body. In doing so, we were able to determine an even greater benefit of the device and develop the Kelling 1.5 in the process…

Written by Doug Stoakley, ClearCam President and COO

2020 was an important and productive year for ClearCam, despite the significant challenges our larger society was confronting with COVID-19. ClearCam, in its 3+ year existence, has been dedicated to innovative research and development, fiscal prudence, and rapid execution. Despite this unprecedented global crisis, we held fast to those guiding principles in 2020.

Written by Dr. John Uecker, ClearCam Co-Founder, CEO

After testing the Kelling in multiple simulation labs and inviting many surgeons to utilize it in those environments prior to the commercial launch, we felt we had a good understanding of the challenges we faced. But we knew that there was going to be a great divide between the laboratory setting and the “real world” clinical setting. Here are the top 5 lessons we have learned since the first clinical case until now (25 cases):

Written by David Poirier, Vice President, Business Development